Sponsored Session: Early Diagnosis of Sepsis Leveraging the Host Immune Response
Sponsored by Immunexpress
The lack of a rapid, sensitive, reliable diagnostic test to provide clinicians with actionable results to rule in sepsis with high confidence is a considerable challenge. Currently they must rely on non-specific clinical assessments, a few broad non-specific biomarkers, and wait 24-72 hours for a confirmatory blood culture. New alternative approaches have been developed which harness the host’s immune response to pathogen invasion. A specific gene signature can be applied to differentiate sepsis from SIRS, serving as a diagnostic guide in clinical decision making and improving patient management and appropriate therapeutic intervention. It is well documented that early diagnosis of sepsis and rapid initiation of therapy can reduce morbidity and mortality as well as improve antibiotic stewardship and reduce hospital costs.
This course was originally recorded in September 2020 as part of the 2020 Sepsis Alliance Summit.
Nurses, physicians, pharmacists, emergency responders, healthcare management teams, and other healthcare staff may benefit.
At the end of the presentation, the attendee should be able to:
- Describe the challenges of current approaches to diagnosing sepsis.
- Explain how the host immune response can be leveraged for early, accurate diagnosis, independent of infecting pathogen and differentiated from SIRS.
- Review summary of results from a clinical trial to validate a host response sepsis diagnostic test.
- Recognize how rapid sepsis diagnosis can lower mortality, improve antibiotic stewardship, and reduce economic burden.
Sepsis Alliance gratefully acknowledges the support provided for this sponsored session by Immunexpress.
Roy F. Davis Ph.D., M.D., MHA
Chief Medical Officer, Immunexpress
Dr. Davis has 30 years’ experience in clinical medicine (Neonatal, Pediatric Critical Care) and hospital administration. He was Clinical Assistant Professor, Department of Pediatrics, University of Washington and served as a consultant in health care standards and quality of care delivered. As CMO at Providence Alaska he assisted in the implementation of MEWS and sepsis surveillance algorithms using the Microsoft Amalga platform across Providence Health & Services, winning a national Microsoft Healthcare innovation award for his work with MEWS in 2012.
No continuing education credits are offered for this sponsored webinar.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.